Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry, Safety, and Efficacy of [177Lu]Lu-XT771 in Recurrent Glioblastoma
NCT07648823Phase 1Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-XT771 in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Primary endpoints: Radiation Dosimetry and Incidence and severity of adverse events and incidence of serious adverse events. Started Jun 2026; status: recruiting.
02
Drugs
[177Lu]Lu-XT771
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07648823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648823.